Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shanghai Invests RMB 120 Million To Boost Biopharma Commercialization

This article was originally published in PharmAsia News

Executive Summary

Shanghai has designated nine key investment areas to boost high-tech industrialization, with the biopharma industry the first to receive funding. The municipal government will allocate a total of RMB 120 million ($17.5 million) to help biopharmaceutical projects and an individual project can receive up to one-tenth of its entire investment. Shanghai Municipality's Science and Technology Commission has published guidelines for fund application. The circular welcomes enterprises in the city that are developing biopharmaceutical products, pharmaceutical chemicals, modernized TCM, medical devices and veterinary drugs, as well as R&D outsourcing companies to submit their projects. Proposals with the potential of being commercialized are a must for obtaining the fund support. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts